Sɔntɛnde yu kin wek na mɔnin ɛn fil se yu stif ɛn stif? Yu tink se i at fɔ bɛn fɔ sɔm tɛm? Dis kin bi bikɔs ɔf Ankylosing Spondylitis , we na wan sik we kin afɛkt di jɔyn dɛn na di spayna. If yu dɔn tray fɔ yuz mɛrɛsin fɔ mek yu nɔ gɛt pen ( NSAID ) we yu nɔ de bay ɛn di pen ɛn swel nɔ dɔn stɔp, yu dɔktɔ kin tɛl yu fɔ tek DMARD. So mek wi go to di bottom of dis.
Wetin na DMARD ɛn aw dɛn de wok?
insay Ankylosing Spondylitis, di difεns sistεm na wi bכdi, di imyun sistεm , de bi ova aktif εn bigin fכ atak wi כwn spεnal jכint dεm. Dis kin mek yu gɛt inflamɛns , pen, ɛn stif we kin mek i nɔ izi fɔ muv di spayna fayn fayn wan.
DMARD na abbrevieshɔn fɔ ‘Disease-Modifying Antirheumatic Drug’ . Fɔ tɔk am simpul wan, i min ‘atraytis mɛrɛsin we de chenj sik’. Dɛn mɛrɛsin ya kin wok bay we dɛn kin mek di imyun sistɛm we de wok pasmak kol. Nɔ lɛk di mɛrɛsin dɛn we dɛn kin yuz fɔ mɛn pen ɔltɛm (NSAID), dɛn tin ya nɔ kin jɔs ridyus di pen, bɔt dɛn kin ɛp bak fɔ kɔntrol aw di sik de go bifo ɛn fɔ mek di jɔyn dɛn nɔ pwɛl mɔ. Na dat mek dɛn kɔl dɛn "disease-modifying" drɔgs.
Us kayn DMARD dɛn kin gi fɔ Ankylosing Spondylitis?
Dɛn kin sheb di DMARD dɛm we dɛn kin gi fɔ dis sik to sɔm men kategori dɛm. Dɛn kɔl dɛn bayolojikal ɛn tradishɔnal DMARD. Lɛ wi tek wan luk pan ɛni wan pan dɛn kayn dɛn ya.
| Di kayn drɔg we dɛn kin yuz | Wan shɔt diskripshɔn |
|---|---|
| Bayolojikal tin dɛn (e.g. TNF inhibito dεm, IL-17 inhibito dεm) | dεn de wok bay we dεn de tכk to spεshal protin dεm we de mek inflameshn na di imyun sistεm. Dɛn kin gi dɛn tin ya bay we dɛn de injɛkshɔn ɔ we dɛn put dɛn insay di bɛlɛ. |
| JAK inhibito dɛn | Dis na nyu kayn DMARD bak. Dɛn tin ya nɔto tin dɛn we gɛt layf. Dɛn kin wok bay we dɛn de tɔch wan grup pan ɛnzaym dɛn we de mek pɔsin inflamɛns. Dɛn kin tek dɛn as pils. |
| Tradishɔnal DMARD dɛn (e.g. Mɛtɔtrɛksɛt, Sɔlfasalazin) | Dɛn kin yuse dɛn tin ya mɔ fɔ at at sik na di periferik jɔyn dɛm, lɛk di an, fut, hip, ɛn ni. Dɛn nɔ kin wok fayn fɔ at at sik na di spayna. |
Biologics: Drugs wae de wok pan di sem target
Bayolojikal tin dɛn tan lɛk snaypa. Dɛn kin tɔch ɛn atak di prɔtin dɛn nɔmɔ we de mek di prɔblɛm dairekt wan.
- TNF inhibito dεm: Dis na di fכs klas fכ bayolojikal dεm we dεn apruv fכ ankylosing spondylitis. Dɛn kin wok bay we dɛn kin blok wan prɔtin we dɛn kɔl Tumor Necrosis Factor (TNF), we kin mek pɔsin inflamɛns. Dɛn kin ɛp fɔ gɛt at at sik na di spayna ɛn ɔda jɔyn dɛm, ɛn bak tin dɛm we kin apin wit di sik, lɛk uveitis , we kin mek yu yay wam, ɛn Inflammatory Bowel Disease (IBD) ( Crohn’s disease and ulcerative colitis). Yu dɔktɔ go ɔltɛm gi yu dɛn tin ya if yu dɔn tray fɔ yuz at le tu kayn mɛrɛsin fɔ mek yu nɔ fil pen (NSAID) ɛn nɔ gɛt ɛni ɛfɛkt.
- Adalimumab (Humira) we de na di bɔdi.
- Sɛrtolizumab (Cimzia) we dɛn kɔl .
- Etanɛsɛpt (Ɛnbrɛl) .
- Infliximab (Rɛmikɛd) .
- Golimumab (Simponi) we de na di bɔdi.
Imajin, wan TNF inhibitor nɔ bin wok fɔ yu. Nɔ wɔri. Di dɔktɔ kin chenj yu to ɔda mɛrɛsin we de na di sem klas. Dɔn, chans de fɔ mek yu gɛt rizɔlt.
- IL-17 inhibito dεm: dεn ya de wok bay we dεn de blכk כda inflammatory protin we dεn kכl Interleukin-17 (IL-17). Dɛn na gud opshɔn fɔ pipul dɛm wae nɔr dɔn ansa to TNF inhibitors ɔ wae nɔr kin tek TNF inhibitors bikɔs ɔf kɔndishɔn dɛm lɛk at sik ɔr multiple sclerosis (MS).
- Ixekizumab (Taltz) we dɛn kɔl Ixekizumab (Taltz) .
- Sekukinumab (Kɔsɛntiks) .
JAK inhibitors: Nyu drɔgs we dɛn kin tek as pils
Dɛn tin ya difrɛn frɔm di tin dɛn we dɛn kin yuz fɔ mek tin dɛn we gɛt layf. Dɛn na gud sɔlvishɔn fɔ pɔsin we nɔ lɛk injɛkshɔn, bikɔs dɛn kin kam insay pil fɔm. Dɛn kin wok bay we dɛn de tɔch wan ɛnzaym sistɛm we dɛn kɔl Janus Kinase (JAK), we kin mek pɔsin inflamɛns.
- Tofasitinib (Xeljanz) we dɛn kɔl .
- Upadacitinib (Rinvoq) we dɛn kɔl Upadasitinib (Rinvoq) .
Tradishכnal DMARD dεm: Na dεn dεm we dεn kin yus fכ di pεrifεral jכint dεm
Dɛn kin gi dɛn tin ya mɔ fɔ pen ɛn swel na di jɔyn dɛn lɛk di an, fut, hip, ɛn ni, pas fɔ mek i fil pen na di spayna.
- Methotrexate: Dis kin kam as pil ɔ injɛkshɔn. I de ɛp fɔ mek di jɔyn dɛn nɔ pwɛl.
- Sulfasalazine (Azulfidine): Dis na tritmɛnt bak fɔ di periferik jɔyn ɛn IBD. Dɛn kin tek am as pil.
Aw dɔktɔ kin pik di rayt DMARD fɔ yu?
Yu dɔktɔ kin tink bɔt bɔku tin dɛn we yu de pik wan mɛrɛsin.
- Aw yu sik dɛn kin rili bad.
- De mɛrɛsin wae yu dɔn yuse trade ɛn de rizulyt wae yu dɔn gɛt frɔm dɛm.
- Di sayd ɛfɛkt dɛm fɔ di mɛrɛsin we dɛn de tɔk bɔt ɛn aw dɛn kin afɛkt yu wɛlbɔdi.
Wetin na di bad tin dɛn we dis mɛrɛsin kin du?
Lɛk ɔl di mɛrɛsin dɛn, DMARD kin gɛt sayd ɛfɛkt. Sɔm na smɔl smɔl tin dɛn, ɛn ɔda wan dɛn kin siriɔs. So tɔk to yu dɔktɔ bɔt dɛn tin ya bifo yu bigin fɔ tek di mɛrɛsin.
- Bayolojikal ɛn JAK inhibito dɛm: Dɛn wan ya de slo di imyun sistɛm, we de mek i nɔ ebul fɔ fɛt infɛkshɔn. So, i impɔtant fɔ mek shɔ se yu no ɔl yu vaysin bifo yu bigin fɔ tek dɛn mɛrɛsin ya.
- Tubakulosis (TB) Tɛst: I impɔtant fɔ mek dɛn tɛst yu fɔ TB (TB) bifo yu bigin fɔ yuz TNF inhibitor, bikɔs dɛn mɛrɛsin ya kin mek di TB jem dɛn we dɔn slip na yu bɔdi wok bak.
- Ɔda bad tin dɛn we kin apin: Di say we dɛn injɛkshɔn kin rɛd, ed kin at, ɛn di skin kin rɔsh. IL-17 inhibito dεm kin mek IBD wכs sכmtεm.
Sayd ifekt dɛm fɔ tradishɔnal DMARD dɛm
- Methotrexate: We yu bɛlɛ at, yu mɔt de so, ɛn yu blɔd sɛl nɔ bɔku, dat kin mek yu gɛt infɛkshɔn, fiva, ɛn brus. Fɔ ridyus dɛn tin ya, yu dɔktɔ go gi yu fɔlik asid tablɛt. We yu de tek dis mɛrɛsin , yu go nid fɔ du blɔd tɛst ɛvri 1-3 mɔnt fɔ chɛk yu kidni ɛn liva fɔ wok. Dɛn nɔ kin advays fɔ tek dis mɛrɛsin we uman gɛt bɛlɛ.
- Sulfasalazine: Nɔs, vɔmit, sɛnsitiv to san layt, skin rash, ɛn ed kin at. Dis mɛrɛsin kin tɔn yu urine, swet, ɛn kray wata to yɔlɔ-ɔrɛnj kɔlɔ. I nɔ denja, bɔt i kin dɔti klos.
Di tin we impɔtant pas ɔl na fɔ nɔ panik if yu gɛt ɛni sayd ɛfɛkt ɛn fɔ tɛl yu dɔktɔ wantɛm wantɛm.
Wetin fɔ ɛkspɛkt we yu bigin fɔ trit yu?
Dɛn mɛrɛsin ya nɔr de woke di sem fɔ ɔlman. Gɛt di rizɔltI kin tek sɔm wik ɔ wan ɔ tu mɔnt. So i impɔtant fɔ peshɛnt. Nɔ stɔp fɔ tek di mɛrɛsin wantɛm wantɛm bikɔs yu tink se i nɔ go bɛtɛ.
Dɔn bak, ivin if yu sik dɔn stɔp kpatakpata, i rili impɔtant fɔ kɔntinyu fɔ tek yu mɛrɛsin fɔ as lɔng as yu dɔktɔ tɛl yu fɔ tek am. If yu stɔp, di sik kin kam bak.
Mɛsej we dɛn kin kɛr go na os
- DMARD nɔ tan lɛk di mɛrɛsin dɛn we dɛn kin yuz fɔ mɛn pen ɔltɛm. Apat frɔm we dɛn de ridyus di pen, dɛn kin kɔntrol bak aw di sik de go bifo ɛn mek di jɔyn dɛn nɔ pwɛl.
- Difrɛn kayn mɛrɛsin dɛn de, lɛk bayolojikal, JAK inhibito, ɛn tradishɔnal DMARD. Yu dɔktɔ go pik di mɛrɛsin we go fayn fɔ yu sik.
- Bikɔs dɛn mɛrɛsin ya de stɔp di imyun sistɛm, dat kin mek i gɛt di sik. I impɔtant fɔ mek dɛn tɛst yu fɔ TB (TB) bifo yu bigin fɔ yuz TNF inhibito dɛn.
- I kin tek tɛm fɔ si di tin dɛn we kin apin, so peshɛnt wit di tritmɛnt we yu de gi yu. Ilɛksɛf yu sik dɔn stɔp, nɔ stɔp fɔ tek di mɛrɛsin if yu dɔktɔ nɔ advays yu.
- If yu gɛt ɛni sayd ɛfɛkt ɔ yu gɛt ɛni prɔblɛm, tɔk to yu dɔktɔ wantɛm wantɛm.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt